Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts
Nuvalent, Inc. (NASDAQ:NUVL) ranks among the best mid-cap stocks with huge upside potential. On August 19, Piper Sandler began coverage of Nuvalent, Inc.
Nuvalent Inc. (NUVL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 17,991,024 | $1,555,863,756 | 23.75% | |
| 2. | Perceptive Advisors Joseph Edelman | 1,562,336 | $135,110,817 | +14% | 3.9% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,400,000 | $121,072,000 | +2% | 5.91% |
| 4. | RA Capital Management Peter Kolchinsky | 1,246,456 | $107,793,515 | 1.33% | |
| 5. | Vestal Point Capital Ryan Wilder | 1,100,000 | $95,128,000 | +3% | 4.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 650,000 | $21,775,000.00 | 650,000 | 2022-11-03 | Filing | |
| $33.50 | 149,253 | $4,999,975.50 | 3,577,267 | 2022-11-03 | Filing | |
| $17.00 | 735,000 | $12,495,000.00 | 3,428,014 | 2021-08-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.42 | 336 | $37,101.12 | 201,672 | 2025-11-24 | Filing | |
| $110.42 | 1,193 | $131,731.06 | 1,377,194 | 2025-11-24 | Filing | |
| $109.77 | 572 | $62,788.44 | 202,008 | 2025-11-24 | Filing | |
| $109.77 | 2,026 | $222,394.02 | 1,378,387 | 2025-11-24 | Filing | |
| $108.73 | 638 | $69,369.74 | 202,580 | 2025-11-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,013,237 | $865,944,758 | 0.05% | |
| 2. | 5,269,433 | $455,700,566 | 12.96% | |
| 3. | 4,605,007 | $398,241,005 | 0.01% | |
| 4. | 4,085,795 | $353,339,552 | 0.01% | |
| 5. | 2,300,865 | $198,978,805 | 0.03% |
News See All
12 Best Mid-Cap Stocks with Huge Upside Potential
The Commerce Department said on August 29 that core inflation, which does not include food and energy expenses, stood at a 2.9% seasonally adjusted annual rate based on the personal consumption expenditures...
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC
Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer
Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
10 Best Debt Free Mid Cap Stocks to Buy Now
Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today's high-interest-rate environment.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Hedge Fund Resource Center Billionaire Hedge Funds
